Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Shengdar Q. Tsai, PhD
Researcher Assistant Member
Experimental Hematology Division
St. Jude Children’s Research Hospital
MS 341, Room D3022B
262 Danny Thomas Place
Memphis, Tennessee, United States
Dr. Shengdar Q. Tsai is an assistant member in the Department of Hematology at St. Jude Children’s Research Hospital. He obtained his B.S. in Biochemistry and Chemistry from the University of Michigan, M.S. in Bioinformatics and Ph.D. in Functional Genomics from North Carolina State University. He was a postdoctoral research fellow and instructor at Massachusetts General Hospital and Harvard Medical School. Dr. Tsai has focused on developing methods for high throughput genome editing with TALENs, and defining and improving the genome-wide specificity of CRISPR-Cas nucleases. His long-term research goals are to develop safe and highly specific targeted genome-editing strategies for treating human genetic diseases.
His research interests include:
• Improving genomic methods to define and measure gene editing “off-target” effects
• Protein engineering of CRISPR-Cas nucleases for precise gene correction
• Regulation of DNA damage repair choice between error-prone non-homologous end-joining and precise homology-directed repair
• Genome-scale CRISPR-Cas screening for novel effectors of hematological diseases
• Developing novel strategies for allele-specific editing of genetic mutations that cause sickle cell disease and other hematological disorders
Related Content
-
Simone C. Eastman Uwan, MDDr. Simone Eastman Uwan was born in Guya...
-
Jeff Glassberg, MDDr. Jeffrey Glassberg obtained his MD an...
-
The Association Between Timely Opioid Administration and Hospitalization in Children With Sickle Cell Disease Presen...Objective: To evaluate the association ...
-
Children’s Hospital of The King’s Daughters Sickle Cell ProgramChildren's Hospital of The King's Daught...
-
Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)GBT440 is First Potential Treatment for ...
-
University of Pittsburgh Medical CenterPeople with inherited blood disorders re...